Pharmacogenetics and epilepsy; analyse van de respons op lamotrigine - Pharmacogenetics of lamotrigine as an antiepileptic drug

Stichting Epilepsie Instellingen Nederland (SEIN)0 个研究点目标入组 200 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•General inclusion criteria
•1. Adult patients with cryptogenic or symptomatic localization-related epilepsy, manifesting in generalized tonic-clonic, complex partial and/or simple partial seizures.
•2. Patients that are able to understand the written information about the study and are able to give informed consent.

•1. Patients failing valproate due to other reasons than persisting seizures despite a maximum tolerated dose (i.e. failure due to adverse effects on a starting dose of valproate, failure due to non-compliance etc).
•2. Patients with generalized epilepsy and/or generalized absence-seizures and /or myoclonic seizures.
•3. Acute or progressive neurological disease.
•4. History of psychiatric disease or substance addiction.

发起方

Stichting Epilepsie Instellingen Nederland (SEIN)